GoKawiilEnveda raises $311M Series E at $2B valuation for AI-driven natural drug discovery
Enveda, a biotech startup using AI to identify drugs from plants and microbes, closed a $311 million Series E funding round at a $2 billion valuation. Catalio Capital Management led the round, with Iconiq and other investors participating. The valuation doubles what the company achieved a year earlier.
GoKawiil's interpretation of the reporting above, not reported fact.
The raise suggests investors remain confident in AI-assisted drug discovery even though no AI-derived drug has yet won FDA approval, according to the reporting. Enveda's multiple candidates already in human trials, including treatments for severe skin conditions and post-GLP-1 weight maintenance, could serve as an early test of whether the AI approach translates into approved medicines.
- Enveda raised $311M in a Series E round led by Catalio Capital Management.
- The new round doubles Enveda's valuation to $2 billion within a year.
- Enveda has several AI-discovered drug candidates already in human clinical trials.
Source: techcrunch.com — Marina Temkin, 2026-09-23
Published there as: “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.